The Manufacturers Life Insurance Company bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 146,854 shares of the company’s stock, valued at approximately $1,514,000.
Other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC bought a new position in Immix Biopharma during the 4th quarter worth approximately $20,471,000. BlackRock Inc. purchased a new position in Immix Biopharma in the 2nd quarter worth approximately $30,827,000. Eventide Asset Management LLC bought a new stake in Immix Biopharma in the fourth quarter valued at approximately $13,331,000. Marshall Wace LLP lifted its position in Immix Biopharma by 3,495.4% in the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after purchasing an additional 1,923,708 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Immix Biopharma during the fourth quarter valued at approximately $8,681,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts have recently issued reports on IMMX shares. Bank of America started coverage on shares of Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating and a $27.00 target price on the stock. HC Wainwright upped their price target on shares of Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Morgan Stanley cut their price target on shares of Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a research report on Friday, August 14th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.29.
Immix Biopharma Stock Performance
NASDAQ IMMX opened at $13.83 on Friday. Immix Biopharma, Inc. has a fifty-two week low of $1.94 and a fifty-two week high of $15.10. The stock has a 50 day simple moving average of $10.95 and a two-hundred day simple moving average of $9.76. The stock has a market cap of $989.40 million, a P/E ratio of -15.72 and a beta of 0.20.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Sell-side analysts predict that Immix Biopharma, Inc. will post -0.74 earnings per share for the current year.
Immix Biopharma Company Profile
Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Stories
- Five stocks we like better than Immix Biopharma
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding IMMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report).
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
